BioSpace News Archive

Pictured: Blue Sanofi sign on building in Germany at night

Business

Sanofi Sells 11 CNS Assets to Pharmanovia including Frisium and Gardenal

The French pharma company continues to pare down its central nervous system business by divesting 11 brands to U.K.-based Pharmanovia, which is expanding its neurology portfolio.

September 19, 2023

·

2 min read

·

Tristan Manalac

Pictured: Gene therapy illustration showing an inj

Policy

FDA Accepts Orchard’s BLA for Rare Disease Gene Therapy Behind EU Approval

Nearly three years after European approval, the U.S. regulator has accepted Orchard Therapeutics’ BLA for its gene therapy OTL-200, being proposed for metachromatic leukodystrophy.

September 19, 2023

·

2 min read

·

Tristan Manalac

External view of Novartis' office in Canada

Business

Novartis Returns Cancer Asset Tislelizumab to BeiGene

After facing regulatory roadblocks, Novartis is returning the anti-PD-1 antibody to the cancer-focused biotech, which regains global rights to develop, manufacture and commercialize tislelizumab.

September 19, 2023

·

2 min read

·

Tristan Manalac

Pictured: U.S. FTC building in Washington, DC/iSto

Policy

Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.

September 19, 2023

·

5 min read

·

Katherine Oluwadarasimi Olowookere

Infectious Disease Contract Research Organization, Microbiologics, Expands its Biosafety Level 3 Laboratory Capacity and Capability

San Diego, California – Leading infectious disease contract research organization (CRO) Microbiologics, has announced an expansion of their Biosafety Level 3 laboratory spaces at the company’s Global Virology Center in San Diego, California.

September 19, 2023

·

2 min read

Drug Development

Astellas Touts Izervay Phase III Geographic Atrophy Data, Eyes Label Expansion

The latest data show Izervay is safe and effective in a two-year trial. Just six weeks after securing FDA approval, Astellas plans to submit it to the regulator to expand its label for a longer treatment timeframe.

September 19, 2023

·

2 min read

·

Kate Goodwin

Pictured: Man holding a cell phone in front of com

Deals

5 Life Sciences IPOs in 2023—and the Future Forecast

After a sluggish start to the year, experts expect an uptick in IPO offerings moving into fall, although it’s unlikely 2023 will fully shrug off its slump.

September 19, 2023

·

5 min read

·

Amanda Heidt

Jointechlabs Makes Microfat-based Regenerative Medical Procedures More Efficient and Profitable

Designed to save a physician time when performing any microfat-based medical procedure, Jointechlabs, Inc. has optimized the components and process of its industry-leading MiniTC® Microfat Processing system.

September 19, 2023

·

2 min read

Pharm Country

National Organization for Rare Disorders Announces More Than $100,000 in Grant Funding Available for Rare Disease Research

The National Organization for Rare Disorders announced three new grant funding opportunities related to the following rare diseases: Arteriovenous Malformation, Levy-Yeboa Syndrome, and Megacystis Microcolon Intestinal Hypoperistalsis Syndrome.

September 19, 2023

·

2 min read

Genetown

eClinical Solutions to Discuss Industry Need for Clinical Data Lakehouse and AI-Enabled Data Management at DPHARM, SCDM, PHUSE EU, Among Other Upcoming Conferences

eClinical Solutions, a global provider of digital clinical software and services, today announced that the company will present at a variety of global industry conferences in fall 2023.

September 19, 2023

·

5 min read